BriaCell Therapeutics Corp. and its subsidiary, BriaPro Therapeutics, have completed an asset purchase agreement granting BriaPro exclusive rights to develop and commercialize the immunotherapy Soluble CD80 (sCD80) for cancer treatment. Originally licensed from the University of Maryland, sCD80 has shown promise in preclinical studies for halting tumor growth by rejuvenating the immune system. As part of the transaction, BriaCell will provide up to $3 million for research and development in exchange for shares, increasing its ownership stake in BriaPro to approximately 78%. Jamieson Bondarenko has been appointed as Chairman of BriaPro’s board. The transaction received overwhelming approval from shareholders, indicating strong support for the strategic move in cancer immunotherapy.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://investingnews.com/briacell-and-briapro-announce-closing-of-asset-purchase-transaction-for-exclusive-soluble-cd80-license/
